116 research outputs found

    Z transform and the use of the digital differential analyzer as a peripheral device to a general purpose computer

    Get PDF
    Z transform and use of digital differential analyzer as peripheral device to general purpose compute

    Linearity Testing of Photovoltaic Cells

    Full text link

    Sny Magill Nonpoint Source Pollution Monitoring Project : final report

    Get PDF
    https://ir.uiowa.edu/igs_tis/1047/thumbnail.jp

    STATUS FISIOLOGIS SAPI SUMBA ONGOLE (Bos indicus) DI KAWASAN PEMBIBITAN SAPI PULAU SUMBA

    Get PDF
    Physiological status is an indicator to determine the degree of health and productivity of livestock. This study aims to identify the physiological status of Sumba Ongole (SO) beef cattle on the island of Sumba by measuring body temperature, respiration frequency, pulse, and body conditioning score (BCS). Overall, there were 70 cows used in the study. Based on gender, there were 21 bulls and 49 cows and they were classified based on age, there were 3 categories, 1-1.5 years, 2-2.5 years, and 3 years. The parameters measured were body temperature, respiratory rate, pulse frequency, and BCS. The results of the study which were processed using analysis of variances (ANOVA) showed that there was no effect of sex or age on body temperature, respiration frequency, pulse frequency (P> 0.05), but there was a significant difference in the age category with the body score of SO cattle (P<0.05). It could be concluded that the physiological status of SO beef cattle which includes body temperature, respiration frequency, and pulse frequency does not show a significant effect on both sex and age, but there is a significant difference in the body score of cattle based on age categories. This research data could probably be used later as a reference for maintaining the health management of SO beef cattle to achieve optimal productivity and profitability

    Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

    Get PDF
    Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

    New fossils of Australopithecus sediba reveal a nearly complete lower back.

    Get PDF
    Adaptations of the lower back to bipedalism are frequently discussed but infrequently demonstrated in early fossil hominins. Newly discovered lumbar vertebrae contribute to a near-complete lower back of Malapa Hominin 2 (MH2), offering additional insights into posture and locomotion in Australopithecus sediba. We show that MH2 possessed a lower back consistent with lumbar lordosis and other adaptations to bipedalism, including an increase in the width of intervertebral articular facets from the upper to lower lumbar column ('pyramidal configuration'). These results contrast with some recent work on lordosis in fossil hominins, where MH2 was argued to demonstrate no appreciable lordosis ('hypolordosis') similar to Neandertals. Our three-dimensional geometric morphometric (3D GM) analyses show that MH2's nearly complete middle lumbar vertebra is human-like in overall shape but its vertebral body is somewhat intermediate in shape between modern humans and great apes. Additionally, it bears long, cranially and ventrally oriented costal (transverse) processes, implying powerful trunk musculature. We interpret this combination of features to indicate that A. sediba used its lower back in both bipedal and arboreal positional behaviors, as previously suggested based on multiple lines of evidence from other parts of the skeleton and reconstructed paleobiology of A. sediba

    Indoor measurement of photovoltaic device characteristics at varying irradiance, temperature and spectrum for energy rating

    Get PDF
    This was accepted for publication in the journal Measurement Science and Technology. The definitive published version can be found at: http://dx.doi.org/10.1088/0957-0233/21/11/115701The first three-dimensional performance matrix for use in photovoltaic (PV) energy rating is reported utilizing a novel energy rating solar simulator based on LEDs. Device characteristics are measured indoors at varying irradiance (G), temperature (T) and spectrum (E). This opens the possibility for a more accurate measurement system for energy yield prediction of PV devices, especially for devices with high spectral dependence such as wide bandgap solar cells as they take into account spectral changes in the light. The main aspects of the LED-based solar simulator used are briefly described. A measurement method is developed and detailed in the paper, which takes into account the current imperfections in the achievable spectrum. Measurement results for a crystalline silicon solar cell are used to demonstrate the measurement approach. An uncertainty analysis of the measurement system is given, resulting in an overall absolute uncertainty of 4.3% (coverage factor k = 2) in maximum power measurements at 765 W m−2 irradiance with scope for further improvements
    corecore